Peer Review Simulator
When to activate
Before submitting a manuscript or grant proposal, after receiving reviewer comments and needing a revision strategy, or when practicing critical evaluation of a draft. Use as a final quality gate before submission.
When NOT to use
Skip for informal writing, blog posts, internal reports not intended for publication, or when you need a specific journal's formatting review (use that journal's checklist instead).
Instructions
Read the full document — manuscript, proposal, or experimental design.
Evaluate against standard criteria:
- Novelty/Significance: Does it address an important gap? Is the advance incremental or substantial?
- Methodology: Are methods appropriate, well-controlled, and sufficiently detailed for replication?
- Statistics: Correct test selection, appropriate sample size, proper reporting (effect sizes, CIs)?
- Data presentation: Are figures clear, properly labeled, with appropriate error bars?
- Literature context: Is the work placed appropriately relative to existing research?
- Conclusions: Are claims supported by the data? Any over-interpretation?
- Writing quality: Clear, logical flow? Grammar and terminology correct?
Generate reviewer comments:
- Major concerns: Issues that must be addressed (missing controls, statistical errors, over-claims)
- Minor concerns: Improvements that would strengthen the work (additional analysis, clearer figures)
- Strengths: What the authors did well (important for balanced review)
Rate severity:
- CRITICAL — Fundamental flaw, invalidates conclusions
- MAJOR — Significant gap, must address before acceptance
- MINOR — Improvement suggested, not blocking
- NIT — Style preference, optional
Output Format
PEER REVIEW: [Document type] — [Title]
OVERALL ASSESSMENT: [Accept / Minor Revision / Major Revision / Reject]
SCORE: [1-9 scale or journal-specific]
STRENGTHS:
1. [Strength with specific reference]
2. [...]
MAJOR CONCERNS:
1. [CRITICAL/MAJOR] — [Issue + specific suggestion for resolution]
2. [...]
MINOR CONCERNS:
1. [MINOR] — [Issue + suggestion]
2. [...]
SPECIFIC COMMENTS:
- Line [X]: [Comment]
- Figure [Y]: [Comment]
- Table [Z]: [Comment]
CONFIDENTIAL (to editor): [Assessment of novelty, competitive landscape]
Example
PEER REVIEW: Manuscript — "Compound X Inhibits Tumor Growth via Novel FAO Pathway"
OVERALL ASSESSMENT: Major Revision
SCORE: 5/9 (interesting but significant gaps)
STRENGTHS:
1. Well-powered in vivo study (n=12/group, appropriate for effect size)
2. Mechanistic depth — metabolomics + CRISPR validation is thorough
3. Dose-response data is clean and convincing
MAJOR CONCERNS:
1. [CRITICAL] — No selectivity data on normal cells. IC50 in HeLa alone doesn't
establish therapeutic window. Must include primary fibroblast or hepatocyte toxicity.
2. [MAJOR] — "Novel FAO pathway" is overstated. Wienert 2023 and Chen 2024 both
described FAO dependency in resistant lines. Reframe as "validated and extended."
3. [MAJOR] — Figure 3B lacks error bars and n is not stated in the legend.
MINOR CONCERNS:
1. [MINOR] — Supplementary Table S2 should include raw data, not just processed means
2. [MINOR] — Discussion paragraph 2 speculates about clinical dosing without PK data
SPECIFIC COMMENTS:
- Line 47: "significant" used without statistical context — add p-value
- Figure 2: Consider log scale for dose-response — improves visual clarity
- Table 1: Add confidence intervals alongside p-values
1---2name: peer-review-simulator3description: Simulates rigorous peer review of manuscripts, grant proposals, or experimental designs. Generates structured reviewer comments with severity ratings and actionable revision suggestions following standard journal review criteria.4allowed-tools: Read, WebSearch5effort: high6metadata:7 source: https://skillmd.com/skills/uitbreidenos/peer-review-simulator8---910# Peer Review Simulator1112## When to activate13Before submitting a manuscript or grant proposal, after receiving reviewer comments and needing a revision strategy, or when practicing critical evaluation of a draft. Use as a final quality gate before submission.1415## When NOT to use16Skip for informal writing, blog posts, internal reports not intended for publication, or when you need a specific journal's formatting review (use that journal's checklist instead).1718## Instructions19201. **Read the full document** — manuscript, proposal, or experimental design.212. **Evaluate against standard criteria:**22 - **Novelty/Significance:** Does it address an important gap? Is the advance incremental or substantial?23 - **Methodology:** Are methods appropriate, well-controlled, and sufficiently detailed for replication?24 - **Statistics:** Correct test selection, appropriate sample size, proper reporting (effect sizes, CIs)?25 - **Data presentation:** Are figures clear, properly labeled, with appropriate error bars?26 - **Literature context:** Is the work placed appropriately relative to existing research?27 - **Conclusions:** Are claims supported by the data? Any over-interpretation?28 - **Writing quality:** Clear, logical flow? Grammar and terminology correct?29303. **Generate reviewer comments:**31 - **Major concerns:** Issues that must be addressed (missing controls, statistical errors, over-claims)32 - **Minor concerns:** Improvements that would strengthen the work (additional analysis, clearer figures)33 - **Strengths:** What the authors did well (important for balanced review)34354. **Rate severity:**36 - CRITICAL — Fundamental flaw, invalidates conclusions37 - MAJOR — Significant gap, must address before acceptance38 - MINOR — Improvement suggested, not blocking39 - NIT — Style preference, optional4041## Output Format4243```44PEER REVIEW: [Document type] — [Title]4546OVERALL ASSESSMENT: [Accept / Minor Revision / Major Revision / Reject]47SCORE: [1-9 scale or journal-specific]4849STRENGTHS:50 1. [Strength with specific reference]51 2. [...]5253MAJOR CONCERNS:54 1. [CRITICAL/MAJOR] — [Issue + specific suggestion for resolution]55 2. [...]5657MINOR CONCERNS:58 1. [MINOR] — [Issue + suggestion]59 2. [...]6061SPECIFIC COMMENTS:62 - Line [X]: [Comment]63 - Figure [Y]: [Comment]64 - Table [Z]: [Comment]6566CONFIDENTIAL (to editor): [Assessment of novelty, competitive landscape]67```6869## Example7071```72PEER REVIEW: Manuscript — "Compound X Inhibits Tumor Growth via Novel FAO Pathway"7374OVERALL ASSESSMENT: Major Revision75SCORE: 5/9 (interesting but significant gaps)7677STRENGTHS:78 1. Well-powered in vivo study (n=12/group, appropriate for effect size)79 2. Mechanistic depth — metabolomics + CRISPR validation is thorough80 3. Dose-response data is clean and convincing8182MAJOR CONCERNS:83 1. [CRITICAL] — No selectivity data on normal cells. IC50 in HeLa alone doesn't84 establish therapeutic window. Must include primary fibroblast or hepatocyte toxicity.85 2. [MAJOR] — "Novel FAO pathway" is overstated. Wienert 2023 and Chen 2024 both86 described FAO dependency in resistant lines. Reframe as "validated and extended."87 3. [MAJOR] — Figure 3B lacks error bars and n is not stated in the legend.8889MINOR CONCERNS:90 1. [MINOR] — Supplementary Table S2 should include raw data, not just processed means91 2. [MINOR] — Discussion paragraph 2 speculates about clinical dosing without PK data9293SPECIFIC COMMENTS:94 - Line 47: "significant" used without statistical context — add p-value95 - Figure 2: Consider log scale for dose-response — improves visual clarity96 - Table 1: Add confidence intervals alongside p-values97```